Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 153Neoplasm Metastasis 10Prostatic Neoplasms, Castration-Resistant 8Neoplasms 6Metastatic Castration-resistant Prostate Cancer 6Breast Neoplasms 6Metastatic Castration Resistant Prostate Cancer 5Prostate Cancer Metastatic 4Metastatic Castration-Resistant Prostate Cancer 4Urogenital Neoplasms 2Prostatic Diseases 2Neoplasms by Site 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Genital Neoplasms, Male 2Castration-resistant Prostate Cancer 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Stage II Prostate Adenocarcinoma 1Salivary Glands Tumors 1Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone 1Prostate Adenocarcinoma 1Pharmacogenetic Study 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Oligometastatic Prostate Carcinoma 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoadjuvant Therapy 1NSCLC Harboring NRG1 Fusion 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1

Interventions

enzalutamide 7Abiraterone Acetate 4abiraterone 3Prednisone 3Docetaxel 3sapanisertib 1relugolix 1pembrolizumab 1onvansertib 1olaparib 1lenvatinib 1inavolisib 1belzutifan 1apalutamide 1abemaciclib 1Prednisolone 1PF06821497 1Methylprednisolone 1Lutetium-177 1Lutetium 1Gonadotropin-Releasing Hormone 1Etoposide 1Dexamethasone 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Metastatic Castration-Resistant Prostate Cancer × Abiraterone Acetate × Clear all
NCT02861573 2026-02-17

KEYNOTE-365

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
1,200 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT04666129 2025-08-17

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
48 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT02405858 2025-02-03

A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy

Janssen Pharmaceutical K.K.

Phase 4 Completed
51 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT02125357 2020-08-07

Sequencing Abiraterone and Enzalutamide in mCRPC

British Columbia Cancer Agency

Phase 2 Completed
202 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡